Tech

CRISPR advances Sickle Cell disease treatment

[ad_1]

The innovative gene-editing technique, CRISPR, has made a remarkable leap from laboratory research to practical medicine by offering a groundbreaking treatment for sickle-cell disease. This debilitating illness, resulting from two defective hemoglobin gene copies, impacts 1 in 4,000 individuals in the US, primarily African-Americans, causing severe pain and limiting life expectancy to around 53 years. Utilizing CRISPR technology, scientists have successfully edited the genes responsible for sickle-cell disease, ultimately correcting the mutation and offering a potential cure for those suffering from this life-altering condition. This medical breakthrough provides hope for sickle-cell patients and establishes a solid foundation for gene-editing techniques to address and potentially cure other genetic disorders.

Bone marrow modification with gene editing

Researchers have found that by making a straightforward DNA modification to bone marrow cells, the body’s alternate hemoglobin production, which typically ceases after birth, can be reactivated. In 2022, Boston-based Vertex Pharmaceuticals became the pioneer in submitting a CRISPR-based therapy for sickle-cell disease for regulatory approval. Clinical trial participants witnessed extraordinary outcomes, with the majority reporting an absence of pain after the bone marrow modification. This groundbreaking therapy offers a promising new treatment option for individuals suffering from sickle-cell disease, potentially improving their overall quality of life and reducing the need for frequent medical interventions. As this gene-editing technique continues to be refined and more patients undergo treatment, the positive results from these initial clinical trials may pave the way for additional CRISPR-based therapies targeting various genetic disorders in the future.

Cost and accessibility of the CRISPR treatment

However, the cutting-edge treatment carries a substantial cost of $2 to $3 million. Additionally, Vertex has not expressed intentions to provide the therapy in Africa, where sickle-cell disease is most widespread and continues to take the lives of children. Despite the steep price tag, there is hope that the treatment could become more accessible to those in need as research progresses and the production cost decreases. In the meantime, efforts to increase awareness and funding for affordable treatments in Africa and other heavily affected areas must not be overlooked, as the demand for effective therapies for sickle cell disease remains high.

The company points to the intricate treatment process, which requires a hospital stay and multiple medical procedures, as the reason for not offering it in nations with restricted healthcare resources. Instead, they emphasize the need for proper infrastructure, advanced equipment, and trained medical professionals to ensure the safe and effective administration of the treatment. In the meantime, they continue collaborating with healthcare authorities and organizations in these nations to explore strategies for overcoming these barriers and making the treatment more accessible.

Developing more cost-effective CRISPR treatments

As a result, scientists are currently concentrating on developing simpler and more cost-effective methods to employ CRISPR in addressing sickle-cell disease. One promising approach involves utilizing CRISPR to edit the genes responsible for sickle cell disease directly in a patient’s bone marrow cells, which could essentially correct the mutation and halt the progression of the disease. This development has the potential to significantly improve the quality of life for millions of individuals affected by sickle cell disease while also reducing the burden on healthcare systems worldwide.

Featured Image Credit: Photo by Pixabay; Pexels

Deanna Ritchie

Managing Editor at ReadWrite

Deanna is the Managing Editor at ReadWrite. Previously she worked as the Editor in Chief for Startup Grind and has over 20+ years of experience in content management and content development.

[ad_2]

Source link

Related Articles